SKB-500 / Sichuan Kelun Pharma - LARVOL DELTA

A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Trial primary completion date: Jul 2025 ➔ Jul 2027

Trial primary completion date • Oncology • Solid Tumor

SKB500 and SKB501: (PRNewswire) - "Novel ADC drugs with verified targets but differentiated payload-linker strategies. The company been received a clinical trial notice approving the IND application of SKB501 and SKB500, respectively, for advanced solid tumors from the NMPA."

New trial • Solid Tumor